Details and Download Full Text PDF:
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).
Blood Adv 2017 Dec 18;1(27):2724-2728. Epub 2017 Dec 18.
Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 -activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)